Greater survival rate from recurrent mouth and throat cancers caused by HPV virus
2/24/2014
People with late-stage cancer at the back of the mouth or throat that recurs after chemotherapy and radiation treatment are twice as likely to be alive two years later if their cancer is caused by the human papillomavirus (HPV), new research led by a Johns Hopkins scientist suggests.
Patients who received daily humidification of the mouth and throat region beginning from day one of radiation therapy treatment spent nearly 50 percent fewer days in the hospital to manage their side effects, according to research presented at the 2014 Multidisciplinary Head and Neck Cancer Symposium.
Limiting radiation to major salivary glands in head and neck cancer patients
2/24/2014
Avoiding the contralateral submandibular gland during radiation therapy is feasible and safe with advanced stage, node positive head and neck cancers and base of tongue lesions, according to research presented at the 2014 Multidisciplinary Head and Neck Cancer Symposium.
Greater survival rate from recurrent mouth and throat cancers caused by HPV virus
2/24/2014
People with late-stage cancer at the back of the mouth or throat that recurs after chemotherapy and radiation treatment are twice as likely to be alive two years later if their cancer is caused by the human papillomavirus (HPV), new research led by a Johns Hopkins scientist suggests.
Effective markers of improved patient outcome: MATH, HPV status in HNSCC
2/24/2014
Evaluating next-generation sequencing (NGS) data and associated clinical records of head and neck squamous cell carcinoma (HNSCC) patients from several institutions, made available through The Cancer Genome Atlas (TCGA), showed that combining Mutant-Allele Tumor Heterogeneity (MATH) as a biomarker with the patient's HPV status provides an effective indicator of improved patient outcome, according...
HPV-positive SCCOP patients' recurrence differs from HPV-negative patients
2/24/2014
Patients with HPV-positive squamous cell carcinoma of the oropharynx (SCCOP) had a longer time to development of distant metastasis (DM) after initial treatment, and had more metastatic sites in more atypical locations compared to HPV-negative patients, according to research presented at the 2014 Multidisciplinary Head and Neck Cancer Symposium.
Identifying men with advanced prostate cancer through genetic screening
2/24/2014
Screening men with a family history of prostate cancer for a range of gene mutations can identify those who are at high risk of aggressive forms of the disease and in need of lifelong monitoring, a new study has shown.
Double the survival rate for HPV-positive OPSCC patients compared to HPV-negative patients
2/24/2014
A retrospective analysis of oropharyngeal patients with recurrence of disease after primary therapy in the Radiation Therapy Oncology Group (RTOG) studies 0129 or 0522 found that HPV-positive patients had a higher overall survival (OS) rate than HPV-negative patients (at two years post-treatment, 54.6 percent vs. 27.
Promising skin tumor vaccine offers hope for transplant patients
2/24/2014
Papillomaviruses (linked to cervical cancer when they infect the mucosal tissue in the female reproductive tract) can also infect normal skin, where they cause warts and possibly non-melanoma skin cancer, mostly in immune-suppressed organ transplant patients. An article published in PLOS Pathogens suggests that vaccination might prevent virus-associated benign and malignant skin tumors.
Selenium and vitamin E supplements 'increase prostate cancer risk'
2/24/2014
A new study recently published in the Journal of the National Cancer Institute suggests that taking high doses of selenium and vitamin E supplements may increase the risk of prostate cancer, depending on a man's selenium levels prior to taking the supplements.The research team, including first author Dr.